

NEWS

30th March 2005

Sydney, Australia – Benitec Limited. (ASX: BLT) advises that the registered office of the company is now at the following address:

Benitec Limited
C/ Whittens Solicitors
Suite 2, Level 30 133 Castlereagh Street
Sydney NSW Australia 2000

Phone: 61 2 9264 2216
Fax: 61 2 9283 1970

About Benitec

Benitec is an international biotechnology company focused on developing therapeutics to treat serious diseases using its proprietary RNAi technology. Benitec (ASX: BLT) is listed on the Australian Stock Exchange and has its clinical operations centered in the heart of Silicon Valley in Mountain View, California, USA. Its lead therapeutic programs are designed to create novel RNAi-based therapies for the Hepatitis C Virus (HCV) and the Human Immunodeficiency Virus (HIV). Benitec's RNA-based HIV therapeutic, co-developed with the Center for Biomedicine & Genetics at the [City of Hope](#) in Los Angeles, California, will enter Phase I clinical trials in 2006.

Benitec Forward-looking Statements

This press release contains forward-looking statements that reflect the Company's current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.

CONTACTS:

BENITEC LIMITED

Australia:
Raymond Whitten
+61 2 9264 2216
rwhitten@benitec.com

United States:
Laurie Reisinger
+650 564 9850 ext.1101
lreisinger@benitec.com

THE RUTH GROUP

United States:
Gregory Tiberend
+646 536 7005
gtiberend@theruthgroup.com